Antiviral resistance during the 2009 influenza A H1N1 pandemic : public health, laboratory, and clinical perspectives
Copyright © 2012 Elsevier Ltd. All rights reserved..
Influenza A H1N1 2009 virus caused the first pandemic in an era when neuraminidase inhibitor antiviral drugs were available in many countries. The experiences of detecting and responding to resistance during the pandemic provided important lessons for public health, laboratory testing, and clinical management. We propose recommendations for antiviral susceptibility testing, reporting results, and management of patients infected with 2009 pandemic influenza A H1N1. Sustained global monitoring for antiviral resistance among circulating influenza viruses is crucial to inform public health and clinical recommendations for antiviral use, especially since community spread of oseltamivir-resistant A H1N1 2009 virus remains a concern. Further studies are needed to better understand influenza management in specific patient groups, such as severely immunocompromised hosts, including optimisation of antiviral treatment, rapid sample testing, and timely reporting of susceptibility results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
The Lancet. Infectious diseases - 12(2012), 3 vom: 10. März, Seite 240-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hurt, Aeron C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 04.04.2012 Date Revised 21.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1473-3099(11)70318-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM214012093 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM214012093 | ||
| 003 | DE-627 | ||
| 005 | 20231224022731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1473-3099(11)70318-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0713.xml |
| 035 | |a (DE-627)NLM214012093 | ||
| 035 | |a (NLM)22186145 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hurt, Aeron C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antiviral resistance during the 2009 influenza A H1N1 pandemic |b public health, laboratory, and clinical perspectives |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2012 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2012 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Influenza A H1N1 2009 virus caused the first pandemic in an era when neuraminidase inhibitor antiviral drugs were available in many countries. The experiences of detecting and responding to resistance during the pandemic provided important lessons for public health, laboratory testing, and clinical management. We propose recommendations for antiviral susceptibility testing, reporting results, and management of patients infected with 2009 pandemic influenza A H1N1. Sustained global monitoring for antiviral resistance among circulating influenza viruses is crucial to inform public health and clinical recommendations for antiviral use, especially since community spread of oseltamivir-resistant A H1N1 2009 virus remains a concern. Further studies are needed to better understand influenza management in specific patient groups, such as severely immunocompromised hosts, including optimisation of antiviral treatment, rapid sample testing, and timely reporting of susceptibility results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Oseltamivir |2 NLM | |
| 650 | 7 | |a 20O93L6F9H |2 NLM | |
| 700 | 1 | |a Chotpitayasunondh, Tawee |e verfasserin |4 aut | |
| 700 | 1 | |a Cox, Nancy J |e verfasserin |4 aut | |
| 700 | 1 | |a Daniels, Rod |e verfasserin |4 aut | |
| 700 | 1 | |a Fry, Alicia M |e verfasserin |4 aut | |
| 700 | 1 | |a Gubareva, Larisa V |e verfasserin |4 aut | |
| 700 | 1 | |a Hayden, Frederick G |e verfasserin |4 aut | |
| 700 | 1 | |a Hui, David S |e verfasserin |4 aut | |
| 700 | 1 | |a Hungnes, Olav |e verfasserin |4 aut | |
| 700 | 1 | |a Lackenby, Angie |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Wilina |e verfasserin |4 aut | |
| 700 | 1 | |a Meijer, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Penn, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Tashiro, Masato |e verfasserin |4 aut | |
| 700 | 1 | |a Uyeki, Timothy M |e verfasserin |4 aut | |
| 700 | 1 | |a Zambon, Maria |e verfasserin |4 aut | |
| 700 | 0 | |a WHO Consultation on Pandemic Influenza A (H1N1) 2009 Virus Resistance to Antivirals |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Infectious diseases |d 2001 |g 12(2012), 3 vom: 10. März, Seite 240-8 |w (DE-627)NLM117564362 |x 1474-4457 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2012 |g number:3 |g day:10 |g month:03 |g pages:240-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1473-3099(11)70318-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2012 |e 3 |b 10 |c 03 |h 240-8 | ||